Brain tumors Survivorship Follow-Up Questions

After treatment for a brain tumor, follow-up has three jobs. It watches for the tumor returning. It manages what treatment left behind. And it deals with the parts of life that changed: driving, working, thinking, mood.

The first job gets most of the appointment time. The other two get the least, and they are the ones that shape daily life. This page is built to help you claim time for all three.

Some scale first. For 2026 the American Cancer Society projects 24,740 new brain and other nervous system cancers in the United States, along with 18,350 deaths. Those are ACS projections, carried on NCI's SEER Stat Facts page. NCI's own SEER measurement, from 2019 to 2023, puts the incidence rate at 6.1 cases per 100,000 people per year. Worldwide in 2022 there were roughly 321,476 new cases.

Ask three specific things about your scans.

First, which scan. NCI describes MRI as having superior soft-tissue resolution. It picks up subtle enhancement, swelling and most kinds of bleeding better than CT. CT is faster and better for calcification, skull lesions and very fresh bleeding, so it has a role in emergencies rather than in routine follow-up.

Second, the interval. Ask how often, for how long, and what would change the schedule.

Third, and most useful, ask what your scans are being compared against. A single image tells you little. A sequence tells you a great deal.

Sometimes a treated area lights up again. That can mean the tumor is back. It can also mean radiation necrosis, which is dead and inflamed tissue where radiation was delivered. On a standard MRI the two can look very similar.

NCI notes that in post-treatment imaging, SPECT and PET may be useful in telling tumor recurrence from radiation necrosis. SPECT is single-photon emission computed tomography. PET is positron emission tomography. Both measure activity rather than structure.

If a follow-up scan shows something new, ask directly: could this be radiation necrosis, and what would distinguish the two? The answer changes everything that follows, and it is a question that is easy to leave unasked in a short appointment.

Seizures are the most common ongoing problem after a brain tumor, and the numbers are higher than most people expect. NCI reports that among all patients with brain tumors, 70 percent of those with primary tumors in the brain tissue itself, and 40 percent of those with tumors that spread from elsewhere, develop seizures at some point.

NCI also notes that in slow-growing tumors, seizures can appear months to years before the tumor is diagnosed.

Practical questions for follow-up:

• Am I on an antiseizure medicine, and is it still needed?
• If I have been seizure-free, is there a plan to reduce or stop it, and over what timeline?
• What does my state require about driving after a seizure, and who documents that I am clear?
• What should someone with me do if I have a seizure, and at what point should they call 911?

Driving rules are set by each state, not by your hospital. Ask the team for the rule in writing so an employer or insurer can see it.

Many people leave treatment on dexamethasone or another corticosteroid to control brain swelling. Steroids work, and staying on them has costs: weight gain, high blood sugar, muscle weakness, thin skin, bone loss, insomnia and mood changes.

Getting off them is a real clinical goal. One trial illustrates how much attention this receives. In a study of bevacizumab added to standard glioblastoma treatment, one of the measured outcomes was corticosteroid use. Patients on bevacizumab started steroids later, at a median of 12.3 months versus 3.7 months. Among those already taking steroids, 66 percent were able to stop, compared with 47 percent on standard therapy.

You do not need to be on that drug for the point to apply. Ask what your current steroid dose is, what the plan is for reducing it, how fast, and what symptoms mean the taper is going too quickly.

Neurocognitive effects are the late effect most likely to be minimized in a short visit. NCI names the risk of neurocognitive deficits explicitly when discussing repeat radiation, alongside the risk of radiation necrosis.

The changes people describe are usually not dramatic. They are slower word-finding, losing the thread in meetings, needing lists for things that used to be automatic, and fatigue that sleep does not fix.

Ask for a formal neuropsychological assessment rather than a bedside memory check. It produces a written profile of what is strong and what is affected. That document is what unlocks rehabilitation, and it is what employers and schools can act on for accommodations.

Ask also about referral to speech and language therapy for word-finding, occupational therapy for planning and organizing, and physical therapy for balance and weakness.

Some brain tumors are watched rather than treated immediately, and survivorship for those people includes a live decision.

The EORTC-22845 trial makes the trade-off concrete. It tested early radiation versus waiting in low-grade glioma. Median progression-free survival was 5.3 years with early radiation and 3.4 years without. Overall survival did not differ: 7.4 years versus 7.2 years. Survival after progression was longer in the group who waited, at 3.4 years versus 1.0 year in the radiation group.

The investigators did not collect reliable quality-of-life data, so it is not known whether the longer time before relapse translated into better function.

If your care includes watchful waiting, this is the study behind it. Ask how it applies to your tumor type and grade.

• What exactly are we watching for on the next scan?
• Is my antiseizure medicine still needed, and what is the plan for it?
• What is my steroid taper schedule?
• Can I have a neuropsychological assessment, and who refers me?
• What can I do about fatigue that is not "rest more"?
• Who do I contact between visits, and for what?
• Can I have a written survivorship care plan?

That last item is the one worth pressing for. A written plan lists the tumor type and grade, every treatment given with doses, the radiation fields, the current medicines, the scan schedule, and the late effects to watch for. Any future doctor can read it in two minutes. Our page on survivorship explains what these plans contain.

If a decision about further treatment feels unclear, getting a second opinion covers how to arrange one without delaying care.

• NCI PDQ on adult central nervous system tumors, for doctors
• NCI PDQ on adult central nervous system tumors, for patients
• SEER Stat Facts: brain and other nervous system cancer (2026 figures projected by the American Cancer Society)